Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
158 hedge funds and large institutions have $1.66B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 23 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 47
19% more capital invested
Capital invested by funds: $1.4B → $1.66B (+$264M)
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
1% more funds holding
Funds holding: 157 → 158 (+1)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
60% less call options, than puts
Call options by funds: $12.6M | Put options by funds: $31.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.5M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$14.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.75M |
| 3 |
Millennium Management
New York
|
-$5.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.78M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$4.38M |
RETA Hedge Fund Activity: Q2 2019 in Review
158 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2019, worth a combined $1.66B — up 19% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RETA positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 47 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $43.6M. The largest seller was Deerfield Management, cutting an estimated $14.4M.
- 158 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2019, up from 157 in Q1 2019.
- Funds reported $1.66B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2019, up 19% quarter-over-quarter.
- 26 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2019 and 23 closed out, a net change of +3 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2019 was Wellington Management Group, an estimated $43.6M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2019 was Deerfield Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2019.